Literature DB >> 24161954

B-Raf mutation: a key player in molecular biology of cancer.

M A Rahman1, A Salajegheh, R A Smith, A K-Y Lam.   

Abstract

B-Raf is one of the more commonly mutated proto-oncogenes implicated in the development of cancers. In this review, we consider the mechanisms and clinical impacts of B-Raf mutations in cancer and discuss the implications for the patient in melanoma, thyroid cancer and colorectal cancer, where B-Raf mutations are particularly common.
© 2013.

Entities:  

Keywords:  B-Raf; BRAF; Colorectal cancer; Melanoma; Mutation; Thyroid cancer

Mesh:

Substances:

Year:  2013        PMID: 24161954     DOI: 10.1016/j.yexmp.2013.10.005

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  16 in total

1.  Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.

Authors:  Sergio Pina-Oviedo; L Jeffrey Medeiros; Shaoying Li; Joseph D Khoury; Keyur P Patel; Khaled Alayed; R Craig Cason; Christopher J Bowman; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.

Authors:  Zi-jie Wang; Zhi-ning Wan; Xu-dong Chen; Chuan-fang Wu; Guo-long Gao; Rong Liu; Zheng Shi; Jin-ku Bao
Journal:  J Mol Model       Date:  2015-04-02       Impact factor: 1.810

3.  Novel FAM134B mutations and their clinicopathological significance in colorectal cancer.

Authors:  Farhadul Islam; Vinod Gopalan; Riajul Wahab; Katherine Ting-Wei Lee; Md Hakimul Haque; Afraa Mamoori; Cu-Tai Lu; Robert A Smith; Alfred K-Y Lam
Journal:  Hum Genet       Date:  2017-01-31       Impact factor: 4.132

4.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas.

Authors:  Md Atiqur Rahman; Ali Salajegheh; Robert Anthony Smith; Alfred King-Yin Lam
Journal:  Endocrine       Date:  2016-05-14       Impact factor: 3.633

6.  Macrophilones from the Marine Hydroid Macrorhynchia philippina Can Inhibit ERK Cascade Signaling.

Authors:  Pengcheng Yan; Daniel A Ritt; Katherine Zlotkowski; Heidi R Bokesch; William C Reinhold; John S Schneekloth; Deborah K Morrison; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2018-07-06       Impact factor: 4.050

7.  Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Authors:  Filip Janku; Eli L Diamond; Aaron M Goodman; Vaijayanthi Kandadai Raghavan; Tamara G Barnes; Shumei Kato; Omar Abdel-Wahab; Benjamin H Durham; Funda Meric-Bernstam; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

8.  Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma.

Authors:  Aaron M Udager; Jincheng Pan; Martin J Magers; Ganesh S Palapattu; Todd M Morgan; Jeffrey S Montgomery; Alon Z Weizer; Khaled S Hafez; David C Miller; James S Wolf; Jonathan B McHugh; Arul M Chinnaiyan; Saravana M Dhanasekaran; Rohit Mehra
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

9.  Metastasis-associated in colon cancer-1 promotes vasculogenic mimicry in gastric cancer by upregulating TWIST1/2.

Authors:  Lin Wang; Li Lin; Xi Chen; Li Sun; Yulin Liao; Na Huang; Wangjun Liao
Journal:  Oncotarget       Date:  2015-05-10

10.  MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.

Authors:  Tina Gruosso; Camille Garnier; Sophie Abelanet; Yann Kieffer; Vincent Lemesre; Dorine Bellanger; Ivan Bieche; Elisabetta Marangoni; Xavier Sastre-Garau; Virginie Mieulet; Fatima Mechta-Grigoriou
Journal:  Nat Commun       Date:  2015-10-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.